Comparison
21q22 11q22 12 Microdeletion Syndrome C5192593 vs 12q14 Microdeletion Syndrome C4305140
Clinical comparison between 21q22 11q22 12 Microdeletion Syndrome and 12q14 Microdeletion Syndrome for differential diagnosis and treatment planning.
21q22 11q22 12 Microdeletion Syndrome C5192593
A rare genetic condition involving deletion of a specific region on chromosome 21. It may cause developmental delay, intellectual disability, and distinctive facial features. Management focuses on developmental support and medical monitoring.
12q14 Microdeletion Syndrome C4305140
A rare genetic deletion involving a segment of chromosome 12. It may lead to developmental delays, learning difficulties, and other health issues. Management is individualized and focuses on supportive therapies.
6 comparison axes
Onset
21q22 11q22 12 Microdeletion Syndrome C5192593
0-0
12q14 Microdeletion Syndrome C4305140
0-2
Onset patterns differ
Severity
21q22 11q22 12 Microdeletion Syndrome C5192593
severe
12q14 Microdeletion Syndrome C4305140
moderate
Different severity levels
Chronic
21q22 11q22 12 Microdeletion Syndrome C5192593
Chronic
12q14 Microdeletion Syndrome C4305140
Chronic
Differing course
Communicable
21q22 11q22 12 Microdeletion Syndrome C5192593
No
12q14 Microdeletion Syndrome C4305140
No
Different transmission
Body System
21q22 11q22 12 Microdeletion Syndrome C5192593
congenital
12q14 Microdeletion Syndrome C4305140
congenital
Same/different system
Category
21q22 11q22 12 Microdeletion Syndrome C5192593
rare-disease
12q14 Microdeletion Syndrome C4305140
genetic
Different category
Bottom line
21q22-11q22-12-microdeletion-syndrome-C5192593 and 12q14-microdeletion-syndrome-C4305140 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 12q14 Microdeletion Syndrome C4305140 | Discriminating power |
|---|---|---|---|
| Developmental delay | May include developmental delay and intellectual disability; severity is described as severe. | May include developmental delay and learning difficulties; severity is described as moderate. | Moderate |
| Facial appearance | Distinctive facial features are mentioned, but specific features are not established here. | No distinctive facial pattern is established in the supplied description. | Low |
| Age at recognition | Supplied onset is at birth (0–0). | Supplied onset spans birth to age 2 years (0–2). | Moderate |
When to favor each condition
Choose 21q22 11q22 12 Microdeletion Syndrome C5192593 when
Chromosomal microarray shows a deletion involving 21q22/11q22.12
The named locus, not clinical severity alone, supports this condition.
High
Severe congenital developmental disability with possible distinctive facies
This pattern is compatible but not diagnostic without genetic confirmation.
Low
Findings recognized at birth
The supplied onset is neonatal, though overlap remains possible.
Low
Choose 12q14 Microdeletion Syndrome C4305140 when
Testing identifies a 12q14 microdeletion
The chromosome 12 locus distinguishes it from a chromosome 21 deletion.
High
Moderate developmental or learning difficulties emerging by age 2
This fits the supplied course but does not prove the diagnosis.
Low
Support needs appear milder than severe intellectual disability
Severity differs in the source data, yet individual variation is not quantified.
Low
How key tests differ
| Test | 21q22 11q22 12 Microdeletion Syndrome C5192593 | 12q14 Microdeletion Syndrome C4305140 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | Deletion involving the specified chromosome 21 region, if present. | Deletion involving 12q14, if present. | The genomic locus is the main discriminator; clinical features alone are insufficient. |
| Developmental assessment | May show more severe developmental or intellectual impairment. | May show delay or learning difficulty, described as moderate. | Assessments guide support but do not establish either diagnosis. |
| Clinical dysmorphology examination | Distinctive facial features may be noted; specifics are not established. | No specific dysmorphic pattern is established here. | Examination findings require correlation with genetic results. |
Prognosis comparison
21q22 11q22 12 Microdeletion Syndrome C5192593
- Outcome
- Chronic congenital condition; detailed outcome and mortality are not established.
- Factors
- Severity is listed as severe; developmental support and monitoring may influence function.
12q14 Microdeletion Syndrome C4305140
- Outcome
- Chronic condition with potentially moderate impact; exact outcome is not established.
- Factors
- Learning needs, associated health issues, and access to supportive care may matter.
Time frame: Lifelong course is implied, but milestones and prognosis are not quantified.
Confirmed locus, developmental profile, associated medical findings, and support services.
Complications comparison
| Complication | Presentation |
|---|---|
| Learning and developmental needs | Intellectual disability and developmental delay may require substantial support. Learning difficulties and developmental delay may require individualized support. The range and frequency of complications are not established in the source. |
| Associated health issues | Additional medical problems are not specified here. Other health issues are mentioned without specific organ involvement. Do not infer particular complications without clinical records and testing. |
| Long-term care burden | Severe designation suggests potentially greater ongoing needs. Moderate designation suggests potentially fewer needs, but this is not quantified. Individual prognosis and complications require clinician assessment. |
Patient education highlights
- HighDiagnosis depends on genetics
A suspected syndrome is not confirmed by appearance or delay alone. Ask about chromosomal microarray or equivalent testing.
- HighSupportive care
Management is individualized and may include developmental therapies and medical monitoring. No specific treatment dose is established here.
- MediumUncertainty
These are rare conditions. Available data do not establish exact symptoms, prevalence, lifespan, or outcomes.